RecruitingNCT03419260

Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children


Sponsor

Children's Hospital of Philadelphia

Enrollment

2,500 participants

Start Date

Mar 13, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

Electrographic seizures are common in critically ill patients leading to increased use of resource-intense continuous EEG monitoring for seizure identification and management. When identified, electrographic seizures are generally treated with anti-seizure medications, but there are very limited data available regarding optimal treatment in terms of the efficacy or safety of specific anti-seizure medications or overall management strategies. This is a single-center prospective observational study. The investigators aim to: (1) track critically ill patients undergoing clinically indicated EEG monitoring and seizure management to identify risk factors for electrographic seizures, (2) create prediction models guiding EEG monitoring resources to the patients at highest risk for seizures, and (3) evaluate our current management strategy in terms of safety.


Eligibility

Min Age: 1 MonthMax Age: 18 Years

Inclusion Criteria3

  • Care in the Children's Hospital of Philadelphia Pediatric ICU.
  • Clinically indicated continuous EEG monitoring.
  • Age > 1 month to 18 years.

Exclusion Criteria2

  • Admitted for Phase 2 (intracranial) EEG monitoring.
  • Intensivist expects to discontinue technological support in the next two days given underlying medical or neurological problems.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERClinically indicated EEG monitoring.

Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.


Locations(1)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03419260


Related Trials